Lilford Richard J, Daniels Benjamin, McPake Barbara, Bhutta Zulfiqar A, Mash Robert, Griffiths Frances, Omigbodun Akinyinka, Pinto Elzo Pereira, Jain Radhika, Asiki Gershim, Webb Eika, Scandrett Katie, Chilton Peter J, Sartori Jo, Chen Yen-Fu, Waiswa Peter, Ezeh Alex, Kyobutungi Catherine, Leung Gabriel M, Machado Cristiani, Sheikh Kabir, Watson Sam I, Das Jishnu
Institute of Applied Health Research, University of Birmingham, Edgbaston, UK.
Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Lancet Glob Health. 2025 May;13(5):e954-e966. doi: 10.1016/S2214-109X(24)00536-9.
The landscape of primary care services in low-income and middle-income country cities is diverse and dynamic, yet the quality of care received is too often low and the financial cost to the patient high. In the second Paper in this Series, we argue that shaping the primary care market is likely to provide larger returns to scale than individual quality improvement initiatives. Among other things, the market can be shaped by regulation and targeted public investment to crowd out poor providers and motivate those that remain to improve. Additional supply-side initiatives for which there is evidence include measures to educate and motivate the workforce, skill substitution and formation of clinical primary care teams, information technology, and improving the supply of medicines and diagnostics. Demand-side measures include reducing out-of-pocket expenses and promoting health literacy and user advocacy. Research is urgently needed into access for people who are unregistered (eg, those who sleep on the streets), those in peri-urban areas and towns, and on cost-effectiveness, and sustainability of beneficial interventions.
低收入和中等收入国家城市的基层医疗服务格局多样且动态变化,但所提供的医疗服务质量往往较低,患者的经济成本却很高。在本系列的第二篇论文中,我们认为,塑造基层医疗市场可能比个别质量改进举措带来更大的规模回报。除其他方面外,市场可以通过监管和有针对性的公共投资来塑造,以排挤不良供应商,并激励留存的供应商进行改进。有证据支持的其他供应方举措包括教育和激励工作人员的措施、技能替代和组建临床基层医疗团队、信息技术,以及改善药品和诊断服务的供应。需求方措施包括减少自付费用,提高健康素养并促进用户维权。迫切需要开展研究,了解未登记人员(如露宿街头者)、城郊地区和城镇居民的就医机会,以及有益干预措施的成本效益和可持续性。